Melanoma is increasing rapidly in incidence and prevalence, especially in younger females
and older males. Treatment options have expanded beyond high-dose interleukin 2 and …

Melanoma is one of the most common cutaneous cancers worldwide. Activating mutations in
RAS oncogenes are found in a third of all human cancers and NRAS mutations are found in …

Opinion statement NRAS mutations in codons 12, 13, and 61 arise in 15–20% of all
melanomas. These alterations have been associated with aggressive clinical behavior and …

Oncogene-targeted therapy is a major component of precision oncology, and although
patients with metastatic melanoma have experienced improved outcomes with this strategy …

Cutaneous melanoma is a devastating form of skin cancer and its incidence is increasing
faster than any other preventable cancer in the United States. The mutant NRAS subset of …

Opinion statement Melanoma is the most aggressive of the cutaneous malignancies,
causing more than 9,000 deaths in the past year in the United States. Historically, systemic …

The treatment of melanoma has been revolutionized over the past decade with the
development of effective molecular and immune targeted therapies. The great majority of …

Melanoma is a cancer of the pigment-producing cells of the body and its incidence is rising.
Targeted inhibitors that act against kinases in the MAPK pathway are approved for BRAF …

The MEK inhibitor MEK 162 is the first targeted therapy agent with clinical activity in patients
whose melanomas harbor NRAS mutations; however, median PFS is 3.7 months …

The treatment of melanoma has improved markedly over the last several years with the
advent of more targeted therapies. Unfortunately, complex compensation mechanisms, such …